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Rodent models of immune-mediated arthritis (RMIA) are the conventional approach to evaluating mechanisms of inﬂammatory
joint disease and the comparative eﬃcacy of antiarthritic agents. Rat adjuvant-induced (AIA), collagen-induced (CIA), and
streptococcal cell wall-induced (SCW) arthritides are preferred models of the joint pathology that occurs in human rheumatoid
arthritis (RA). Lesions of AIA are most severe and consistent; structural and immunological changes of CIA best resemble
RA. Lesion extent and severity in RMIA depends on experimental methodology (inciting agent, adjuvant, etc.) and individual
physiologic parameters (age, genetics, hormonal status, etc.). The eﬀectiveness of antiarthritic molecules varies with the agent,
therapeutic regimen, and choice of RMIA. All RMIA are driven by overactivity of proinﬂammatory pathways, but the dominant
molecules diﬀer among the models. Hence, as with the human clinical experience, the eﬃcacy of various antiarthritic molecules
diﬀers among RMIA, especially when the agent is a speciﬁc cytokine inhibitor.
1.Introduction
Imbalances in proinﬂammatory and anti-inﬂammatory
immunomodulatory pathways can promote autoimmune
responses that manifest as chronic inﬂammatory conditions.
Diarthrodial joints (those with cartilage-capped surfaces, an
intervening space ﬁlled with viscous ﬂuid, and a synovium-
lined capsule) are one major target of autoimmune attack.
The classic immune-mediated joint disease in humans is
rheumatoid arthritis (RA). The impact of this ailment on
both individuals and society at large is immense. The
estimated worldwide prevalence of RA is 1% to 2%. Relative
to healthy individuals, RA patients have three times greater
direct healthcare costs and are also two times more likely
to require hospitalization and ten times more likely to be
disabled [1, 2].
The exact etiology (cause) and pathogenesis (mecha-
nisms) of autoimmune joint diseases are uncertain. Current
thinking is that the primary arthropathic immunological
defects may include constitutive activation of immune
surveillance cells [3] resulting in persistent relative over-
production of proinﬂammatory [4–7] and proerosive [8–
10] cytokines and abnormal recognition of self-antigens as
nonself due to their similarity with a foreign protein [3,
11–13]. The nature of the immunoregulatory disturbance
diﬀers among individuals, a fact indicated by the divergent2 Journal of Biomedicine and Biotechnology
responses of RA patients to cytokine-speciﬁc biopharma-
ceutical inhibitors [7, 14]. Thus, RA is actually a syndrome
in which a common set of structural changes is provoked
by one or more of several cellular/molecular aberrations.
Multiple factors including age, gender (hormonal status),
geneticbackground,andenvironmentalconditionsinﬂuence
the molecular events that regulate the onset and persistence
of RA in people [15].
2. Objectives of the Review
Various rodent models of immune-mediated arthritis
(RMIA) have become the standard means of evaluating
hypothetical mechanisms of immune-mediated joint disease
and for testing the comparative eﬃcacy of novel antiarthritic
drug candidates during preclinical development [16, 17].
The current paper has multiple objectives. First, available
RMIA options will be listed and their features brieﬂy
summarized. Second, the biological attributes of major
RMIA will be compared. Third, a subset of these RMIA
will be recommended as the most appropriate surrogates for
human RA and a rationale given for this selection. Fourth,
procedures for the reliable production and assessment of
the recommended RMIA will be described. Finally, practical
principles that must be considered during RMIA selection
and experimental design during preclinical drug develop-
ment will be deﬁned. The larger joint size in nonrodent
models such as rabbits [18–20] or nonhuman primates
[21, 22] may be the more appropriate model for preclinical
investigation for some purposes. Nonetheless, this paper
does not address analysis of immune-mediated joint disease
in nonrodent models because they are used less commonly
than RMIA [16].
3. Objective1: Available Rodent Models of
Immune-MediatedArthritis(RMIA)
ManyRMIAhavebeenevaluatedduringthepastﬁvedecades
as potential models for evaluating immune-mediated joint
injury. Some are suitable chieﬂy for evaluating cellular
and molecular mechanisms of disease, while others may
be employed to investigate both arthritis mechanisms and
antiarthritic eﬃcacy. The available RMIA options may
be categorized in several fashions, including by aﬀected
species (rat, mouse, and guinea pig), disease type (genet-
ically engineered, induced, or spontaneous), and inciting
agent (e.g., chemicals, collagen, or exogenous polysaccha-
rides/proteins/proteoglycans). This section uses all these
classiﬁcation schemes to provide a brief overview of possible
and preferred RMIA.
3.1. Rodent Species Employed in RMIA Experiments. Rats and
mice are the most common RMIA used for contemporary
arthritis investigation [16] and are the focus of the current
review. Guinea pigs are employed occasionally in immune-
mediated arthritis research, primarily to explore basic mech-
anisms [18, 23–26].
Rodents oﬀer many advantages as research subjects for
arthritis studies. First, their inexpensiveness, small size, and
receptiveness to group housing substantially reduce research
costs relative to studies in nonrodents. Second, many diﬀer-
entrodentstocksandinbredstrainsmaybeusedtoassessthe
impact of biological heterogeneity on arthritis progression.
Rodent strain-speciﬁc [27, 28] and even substrain-speciﬁc
[29] genetic attributes as well as divergent immunological
capacities [30, 31] can modulate the extent and severity
of immune-mediated diseases; importantly, an analysis of
conserved chromosomal homology among rats, mice, and
humans suggests that arthritis susceptibility loci are highly
conserved across these species [27, 28, 32]. Third, modern
techniques allow deliberate alteration of the rodent genome
to evaluate molecular mechanisms that regulate immune-
mediated joint disease (e.g., [33–36]). Fourth, procedures
for initiating and evaluating RMIA have been well charac-
terized and may be undertaken with inexpensive laboratory
equipment (see below). Fifth, as mice (and rats) are the
main species used for immunological research, numerous
complementary reagents (e.g., cytokines and anticytokine
antibodies) arereadily availableforthesetwo species.Finally,
the animal models of RA with a well-proven track record for
predicting whether or not novel antiarthritic agents might
be useful in human patients are all performed in rodents
[16, 37]. The closest resemblance to RA among the induced
RMIA is the joint lesions in collagen-induced arthritis (CIA)
[38, 39].
For each rodent species, susceptibility to immune-
mediated arthritis is limited to certain strains and stocks.
For rats, the inbred DA and Lewis strains are susceptible
to arthritis induction (Figure 1), while the inbred BN and
F344 (Fisher) strains are relatively resistant [27]. Arthritis-
sensitive mice include B10.Q, B10.RIII, and DBA/1 inbred
strains [40, 41]. Susceptible rodent strains are not equally
vulnerable to all arthritogenic agents. For example, the DA
rat develops AIA after one subcutaneous injection of incom-
plete Freund’s adjuvant (IFA), while other rat strains are not
sensitive to this very weak agent [42]. Furthermore, even
within the sensitive DA rat strain, arthritis susceptibility is
not uniform, as diﬀerent substrains exhibit varying propen-
sities for developing common induced forms of immune-
mediated arthritis [29]. The same genetic manipulation
may produce polyarthritis in one strain without causing
lesions in another; an example is the genetically engineered
null mutation in interleukin-1 receptor antagonist (IL-1ra),
where the knockout genotype yields a clinically prominent
arthritis phenotype in BALB/c mice but does not aﬀect
C57BL/6 mice [33]. Arthritis is more severe and prolonged
if the inciting agent is a self-antigen, such as mouse type
II collagen, rather than an exogenous arthritogen [42, 43].
These distinctions indicate that the suitability of each RMIA
should be reestablished each time it is imported into a new
research facility and again on each occasion when the animal
supplier is changed.
3.2. Available Options for Investigating Immune-Mediated
Arthritis in Rodents. T h r e eb r o a dc l a s s e so fR M I Am a yb e
used to evaluate disease mechanisms and/or the potentialJournal of Biomedicine and Biotechnology 3
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Figure 1: The ability to model immune-mediated disease is
aﬀected by many factors, including the animal strain (top triangle),
the choice of model (middle triangle), and the nature of the
antiarthritic molecules being tested (bottom triangle). For rat
strains, susceptibility to arthritis is highest in DA and lowest
in F344 animals. For rat model systems, the adjuvant-induced
arthritis (AIA) variants are more aggressive than are the collagen-
induced arthritis (CIA) and streptococcal cell wall (SCW) versions;
furthermore,theextentofAIAlesionsdependsontheincitingagent
(lipoidal amine (LA) versus heat-killed Mycobacterium (Myc)),
while the severity of the CIA lesions is more extensive if the
source of incomplete Freund’s adjuvant (IFA) is Sigma Chemical
C o .( S t .L o u i s ,M O )r a t h e rt h a nD i f c oL a b o r a t o r i e s( D e t r o i t ,M I ) .
With regard to treating rats with CIA, the greatest improvement
in joint disease is achieved using the cytokine-inhibiting biologics
interleukin-1 (IL-1) receptor antagonist (IL-1ra) and soluble tumor
necrosis factor (TNF) receptor (sTNFR) and intermediate using
small molecule blockers of p38 kinase (which regulates IL-1 and
TNF). Depending on the treatment window, cyclosporin A (CsA)
will inhibit, delay, or even exacerbate arthritis in Lewis rat CIA
(compare also to Figure 8).
eﬃcacy of novel antiarthritic molecules. These categories are
induced, genetically engineered, and spontaneous disease. In
general, mechanistic studies may be undertaken using RMIA
from any of these classes, while eﬃcacy studies performed
during preclinical drug development usually employ one or
moreinducedmodels(sometimessupplementedwithawell-
chosen genetically engineered model).
Induced RMIA. These models result from administration
of an exogenous material and can be separated into
several categories depending on the type of insult [44,
45]. Many variants develop from injected molecules. The
ﬁrst option, adjuvant-induced arthritis (AIA), results from
intradermal administration of various oil-based chemi-
cals. The traditional example is administration of heat-
killed Mycobacterium tuberculosis in IFA (AIA-Myc), but
comparable lesions result from introduction of various
chemicals in IFA including avridine, heptadecane, lipoidal
amine, pristane, or squalene, or by injection of IFA alone
[46, 47]. Rats are susceptible to all these AIA models,
while mice are resistant to classic AIA variants [48]e x c e p t
for pristane [27]. The second alternative, collagen-induced
arthritis (CIA), is elicited reliably in both rats [39]a n d
mice [49] by hyperimmunization with homologous or
heterologous type II collagen in IFA. The third option is
injectionofbacterialcellwallpeptidoglycan(polysaccharide)
fragments [50, 51]. The classic example is streptococcal cell
wall-induced arthritis (SCW), although other entities like
Lactobacillus or Mycoplasma cell wall fragments, β-glucan,
and lipopolysaccharide are also arthritogenic [47, 52, 53].
The bacterial fragments may be injected locally (i.e., intra-
articular) or systemically. Disease severity and progression in
rats is greatest for AIA, intermediate for CIA, and least for
SCW (Figure 1). Adaptations of AIA, CIA, and to a lesser
extent SCW are the current workhorse RMIA for preclinical
drug development [16]( T a b l e1).
Other induced RMIA are used less frequently for product
registration but still have considerable value for investigating
mechanistic questions. The fourth induced RMIA option
is to administer an exogenous protein into the joint of
an antigen-immunized animal to produce antigen-induced
arthritis (AntIA). In this model, initial subcutaneous immu-
nization induces antibody production, after which subse-
quent intra-articular introduction of the antigen attracts
antibodies into the joint. Classic antigens for AntIA include
bovine serum albumin, ovalbumin, horseradish peroxidase,
and keyhole limpet hemocyanin [54–56]. Persistence within
the synovium of many of these antigens, especially those
with a cumulative positive charge [57], appears to be a
major factor in the development of chronic synovitis. A ﬁfth
induced RMIA, antibody-induced arthritis (AbIA), arises
following local (intra-articular) or systemic introduction
of monoclonal antibodies (typically a multiagent cocktail)
directed against type II collagen or other self antigens that
are highly expressed in joints [18, 58–61]. In this model,
antibodies must enter the joint to encounter their antigen.
These models typically present as a mild, acute lesion relative
to the joint alterations produced by other inciting agents.
A sixth alternative is to inject proinﬂammatory cytokines
directly into a joint (usually the tibiotarsal joint (knee)
d u et oi t sl a r g ev o l u m e )t oi n d u c ea na c u t es y n o v i t i s[ 62,
63]. Interestingly, IL-1β and TNF-α produce distinct, time-
dependentpatternsofacutearthritisintheratkneefollowing
direct injection [62]. Thus, this RMIA has utility not only
to investigate proinﬂammatory mechanisms but also as a
means of predicting potential schedules, relative potencies,
and comparative eﬃcacies of various inhibitors of cytokine
blockers.
Two other induced RMIA provoke subcutaneous lesions
that serve as faux joints rather than immune-mediated
disease of the rodent’s own diarthroidal joints. The ﬁrst vari-
ant involves surgical implantation of human joint tissue—
normal or inﬂamed articular cartilage and/or synovium—
into SCID (severe combined immunodeﬁciency) mice [64–
66]. The second option is introduction of sterile air into the
subcutistoinitiateapouchgranuloma[67],thewallofwhich
exhibits many similarities to synovium [68, 69]. Subsequent
injection of such molecules as carrageenan [70], γ-globulin
[71] ,s t r e p t o c o c c a lc e l lw a l lf r a g m e n t s[ 72], or zymosan4 Journal of Biomedicine and Biotechnology
[73] incites an inﬂammatory response in the pouch that
morphologically resembles acute and chronic synovitis [44].
Bothxenograftsandairpouchescanbeemployedtoevaluate
the eﬃcacy of therapeutic agents on synovitis and cartilage
degeneration [73, 74]. Advantages of these two RMIA are
their conceptual simplicity, their ability to incorporate tissue
from normal and RA-aﬀected human joints, and their large
dimensions (relative to the size of rodent joints). However,
their main disadvantages are that these subcutaneous sites
do not recapitulate the normal joint structure (because they
usuallylackcartilage)andfunction(becausetheydonotbear
weight).
Genetically Engineered RMIA. These models have been
deliberately constructed by gene targeting (mice only) or
transgenic technology to overproduce, underexpress, or
lack one or more immunoregulatory molecules (ligands or
receptors) (Table 1). In most instances, engineered RMIA
are generally used for basic experiments to explore proposed
molecular mechanisms although they can be employed to
evaluate the eﬃcacy of therapeutic candidates designed
to impact a particular immunoregulatory pathway [45].
Important transgenic mouse models of arthritis express
human major histocompatibility complex (MHC) class II
allele HLA-DR [35, 75, 76] or overexpress proinﬂammatory
cytokines like tumor necrosis factor-α (TNFα;[ 34, 77]) or
enzymes that degrade articular components (e.g., matrix
metalloproteinases (MMP); [78]) or critical T lymphocyte
receptors [36, 79]. Other signiﬁcant mouse arthritis mod-
els have been constructed to lack endogenous cytokine
inhibitors such as IL-1ra [33, 80]. In some instances, engi-
neered mouse models of arthritis carry two or more genetic
alterations; a well-known example is the K/BxN mouse,
which expresses both a human T-cell receptor transgene
(designated KRN) and the human MHC class II molecule
A(g7) [36, 61]. The principal genetically engineered rat
arthritis model carries transgenes for both the human MHC
class I allele HLA-B27 and human β2-microglobulin [81, 82]
and develops an immune-mediated joint disease which more
closely resembles ankylosing spondylitis in humans rather
than RA. Defective function of all these molecules has been
linked in humans to RA and ankylosing spondylitis [7,
83–85]. Symmetrical polyarthritis in genetically engineered
r o d e n t sd e v e l o p sa tv a r i o u st i m e sa m o n gt h ed i ﬀerent
models, with the span required for 100% penetrance ranging
f r o m3t o4w e e k so fa g ei nT N F α-transgenic mice [77]t o
13 weeks of age in IL-1ra knockout mice [33]. The hock
(ankle) joints appear to be the earliest and most commonly
targeted sites in most models although other regions such
as the interphalangeal (toe) and coxofemoral (hip) joints are
attacked as well or even preferentially in some models.
SpontaneousRMIA. Naturallyoccurringanimalmodelswith
immune-mediated joint disease resembling human RA are
rare (Table 1). The classic example is the MRL/Mpj-lpr/lpr
(MRL/lpr) mouse, which develops a systemic autoimmune
disease that includes joint involvement. Polyarthritis with
pannus formation and cartilage degeneration primarily
involving the hind limbs develops by ﬁve months of age in
associationwithantibodiestotypeIIcollagen[86,87].Onset
oftheconditionisassociatedwithseveralimmunoregulatory
deﬁciencies including macrophage activation [88, 89]a n d
altered production of various cytokines [90, 91].
4.Objective2:ComparativeBiology of Rodent
Models of Immune-MediatedArthritis
4.1.MorphologicLesionsinRMIA. AllRMIAhavepathologic
features that are reminiscent to some degree of the typical
lesions observed in the human RA joint. The RMIA resulting
from systemic exposure to an arthritogen generally aﬀect
multiple joints and usually develop ﬁrst in the hind paws
[87, 92–94]. In contrast, targeted induction of RMIA by
direct injection of an agent into a single joint usually yields a
monoarticular disease [6, 41, 62]. Indeed, some researchers
use the contralateral joint as an untreated control tissue
although this practice is questionable since lesions also may
be induced in the uninjected knee [20].
The structural appearance of aﬀected joints in RMIA
exhibits an overlapping spectrum of changes, the exact
nature of which depends on both the inciting agent and
the length of time over which arthritis has been allowed to
progress. Findings may be classiﬁed using structural eﬀects
(inﬂammation, skeletal damage, and vascular changes) or
temporal criteria (acute (early) and chronic (late) clinical
stages). Acute lesions [59, 62, 95]a r ec h a r a c t e r i z e db ys u b -
stantial soft tissue edema, an extensive inﬂux of neutrophils
with lesser numbers of mononuclear leukocytes (chieﬂy
lymphocytes and macrophages), abundant extravasation
of ﬁbrin, and modest synovial hyperplasia and skeletal
erosion. Progression over time results in chronic lesions
characterizedbysubstantialsynovialhyperplasia,production
of ﬁbrovascular tissue sheets (pannus) that extend from the
synovium into the joint space, matrix degeneration in the
articular cartilage, and extensive inﬁltration of perivascular
softtissueswithamixedinﬂammatorycellinﬁltrateinwhich
lymphocytes, macrophages, and plasma cells predominate;
neutrophils, ﬁbrin, and soft tissue edema are understated
if present at all in such established lesions [8, 93, 94, 96].
Skeletal erosion begins one to two days after the paw
swelling associated with acute synovitis develops [93, 94].
Left untreated, the extent of cartilage matrix degeneration
(speciﬁcally proteoglycan loss in the articular surface [97])
and bone attrition increases rapidly over time [8, 93, 94,
98]. The widespread formation of osteophytes along the
p e r i o s t e a ls u r f a c ei ns o m eR M I A( A I A> CIA   SCW) may
eventually result in fusion (ankylosis) of the aﬀected joints.
The bone marrow, including that in the cores of osteophytes,
in some RMIA (AIA   CIA > SCW) contains myriad
inﬂammatory cells and activated osteoclasts early during
disease. However, over time both these cell populations
r e g r e s st ob er e p l a c e db yﬁ b r o u sc o n n e c t i v et i s s u eo rf a t[ 99].
Vascular proliferation in the synovium and periarticular soft
tissues is a prominent component of some RMIA [100, 101].
Joint involvement varies among RMIA. For example,
arthritis in AIA-Myc in Lewis rats reliably occurs early in the
tibiotarsal and intertarsal joints (hock (or “ankle”)) of the
hind paws [102] and also in the femorotibial joints (knee)Journal of Biomedicine and Biotechnology 5
Table 1: Common rodent models of immune-mediated arthritis used in preclinical development of antiarthritic therapies.
Categories Induction principle Examples Inciting agents/genetic alteration Species
Genetically
engineered
Deliberate manipulation of one or more
genes encoding proteins that regulate the
immune response
HLA-B27
transgenic
Human leukocyte antigen (HLA) B27 (a major
histocompatibility complex (MHC) class 1
molecule) and human β2-microglobulin
Rat
HLA-DR
transgenic
Human leukocyte antigen, D-related (a MHC
class II molecule) Mouse
IL-1ra knockout Interleukin-1 receptor antagonist Mouse
K/BxN Human T-cell receptor (KRN) and a human
MHC class II molecule Mouse
TNF-α transgenic Tumor necrosis factor-α Mouse
Induced Administration of an exogenous material
Adjuvant-induced
arthritis (AIA)
Lipoidal amine Rat
Mycobacterium tuberculosis Rat
Pristane Mouse,
rat
Collagen-induced
arthritis (CIA) Type II collagen (bovine, porcine, and rodent) Mouse,
rat
Bacterial cell
wall-induced
arthritis
Bacterial cell wall peptidoglycan (polysaccharide):
Lactobacillus sp., Streptococcus sp. (SCW) Rat
Spontaneous MRL/lpr MRL/Mpj-lpr/lpr Mouse
(Figure 2) but does not develop in the forepaws until much
later. Lesions in Lewis rats with AIA-LA are evident in the
knee but not in the ankle (Figure 2) or forepaws. In contrast,
jointsofboththeforepawsandthehindpawsareinvolvedin
LewisratswithCIA.Thedegreeofhindpawswellingismuch
greater for both AIA models than it is for CIA (Figure 3)o r
SCW.
As in RA, immune-mediated polyarthritis in RMIA
can have systemic consequences. Extra-articular structural
changes observed in rat AIA include autoimmune reactions
at other sites (e.g., blood vessels, brain, and uvea of the eye),
bone loss in the axial skeleton, bone marrow hyperplasia
(accompanied by multilineage leukocytosis), and reactive
hyperplasia with enlargement of regional lymph nodes and
spleen [10, 94, 103]. In contrast, the main extra-articular
eﬀects observed in rat CIA are concomitant bone loss in
the axial skeleton [10] and reactive hyperplasia but not
enlargement limited to the regional lymph nodes [93].
Signiﬁcant systemic eﬀects are not evident in rat SCW [104].
The pathologic presentation of RMIA diﬀers distinctly
from that of human RA in several critical respects [37]. First,
rodents exhibit more prominent damage to the articular
surface (full-thickness cartilage matrix degeneration with
later cartilage dissolution; [8]) and adjacent bone (ranging
from partial erosion to complete penetration of the original
cortex accompanied by exuberant formation of periosteal
osteophytes; [8, 94, 105]). These changes are evident even in
those RMIA in which pannus is a less prominent element of
the joint lesion (e.g., AIA-Myc, acute SCW). Another diﬀer-
ence is the accelerated progression of joint damage in RMIA
(daystoafewweeks)relativetodiseaseevolutioninRAjoints
(months to years). Corollaries to this rapid advancement in
RMIA are that the nature of the inﬂammatory changes at the
time of peak joint damage is subacute (i.e., includes a greater
inﬂux of neutrophils and more edema) relative to RA, and
that the severe destabilization of massively eroded joints in
RMIA leads to early and extensive ankylosis, which is rarely
seen in human adult RA. Finally, a much greater degree of
osteoclast production is evident in aﬀected joints in RMIA
[102].
4.2. Mechanisms That Regulate Joint Disease in
Rodent Models of Immune-Mediated Arthritis
4.2.1. Involvement of Cellular and Humoral Immunity. Initial
onset of synovitis in RMIA results from innate immunity,
but disease progression is a consequence of both cell-
mediated (Th1-type) and humoral (antibody-based, or Th2-
type) immune responses. The degree to which these systems
regulate lesion evolution varies among models, but disease
is most severe when both cellular and humoral branches are
invoked [106]. Both innate immunity (via early inﬁltration
by neutrophils and later production of macrophages) and
acquired immunity (through expansion of sensitized B-
and T-lymphocyte lineages) are involved. The initial intra-
articular driving force in induced RMIA appears to be
deposition of exogenous antigens in synovial blood vessels
[92] except for CIA, where the earliest event is thought to
be production of anticollagen antibodies leading to immune
complex deposition on and in the articular cartilage [41].
A l lR M I Aa sw e l la sR A[ 107]a r ed r i v e nb yc e l l -
mediated immunity, reﬂecting the activity of sensitized
autoimmuneTlymphocytesoftheT-helper(Th)phenotype.
This dependence is shown by the ability to pass rat AIA
[11, 108, 109]a sw e l la sr a t[ 110]a n dm o u s e[ 111]C I At o
nonimmunized (naive) recipients by transferring sensitized6 Journal of Biomedicine and Biotechnology
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Figure 2: Related rodent models of immune-mediated arthritis (RMIA) will respond in similar or diﬀerent manners, depending upon the
parameter being assessed. Rat adjuvant-induced arthritis initiated with lipoidal amine (AIA-LA) or heat-killed Mycobacterium tuberculosis
H37Ra (AIA-Myc) develops 9 days after adjuvant injection. Both models exhibit similar declines in total body weight (a), increases in hind
paw volume (b), and reductions in bone mineral density (BMD) in the knee (femorotibial joint) (c). However, BMD in the ankle (tibiotarsal
and intertarsal) joints is reduced only in AIA-Myc (c). Another diﬀerence between the two models is the nature of the dose-response curve
for inducing arthritis (d); the proinﬂammatory response to Mycobacterium H37Ra is linear across a broad dose range, while the response to
lipoidal amine exhibits an abrupt threshold (at 50mg/mL) below which adjuvant injection does not produce disease. Both AIA models were
induced in young adult (7- to 8-week-old), male Lewis rats. Lipoidal amine was given as a single intradermal injection of 5mg (in 0.1mL of
complete Freund’s adjuvant; Difco Laboratories, Detroit, MI) at the tail base, while H37Ra was generated and administered as described in
Section 6. Bars associated with data points represent standard error of the mean.
T-cells from aﬀected donors and by the inability to induce
AIA [27]o rS C W[ 112] in athymic rats. A major function
of the sensitized autoimmune cells is recognition of type II
collagen as a substrate [113].
Humoral immunity resulting from B-lymphocyte activ-
ity and plasma cell proliferation is a feature of many RMIA
and RA. Anticollagen antibodies are found in CIA [114, 115]
and in some [116, 117]b u tn o ta l l[ 27] AIA variants, as
well as in many RA patients [118, 119]. Indeed, activity
of B-lymphocytes is absolutely required for CIA induction
as joint disease does not develop in B-cell-deﬁcient mice
[120]. Accumulation of immune complexes both in articular
cartilage and in circulation is a common feature of many
RMIA[87,121,122].Introductionofanticollagenantibodies
in the absence of sensitized lymphocytes can induce arthritis,
although in the absence of T-helper cells to boost the
immune response, the antibody-driven disease is transient
a n dm i l d[ 114, 123]; this outcome suggests that the role ofJournal of Biomedicine and Biotechnology 7
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2.5–4
2.5–4
1–1.2
0.4–0.6
Figure 3: The severity of immune-mediated joint disease in rats
varies with the model and the choice of reagents. Adjuvant-induced
arthritis induced in young adult, male Lewis rats using either
lipodal amine (AIA-LA) or Mycobacterium tuberculosis (AIA-Myc)
produces extreme swelling and reddening of the tibiotarsal region
(hock (or “ankle”)) (upper image) relative to the changes that
develop in young adult, female Lewis rats with collagen-induced
arthritis (CIA). The degree of hock expansion associated with CIA
induction using incomplete Freund’s adjuvant (IFA) from Sigma
Chemical Co. (St. Louis, MO) (middle image) is greater than that
associated with IFA provided by Difco Laboratories (Detroit, MI)
(lower image). Intra-articular inoculation of streptococcal cell wall
(SCW) polymers results in modest hind paw swelling (not shown).
humoralimmunityinRMIAmaybesubsidiarytothatplayed
by the cell-mediated immune response. Antibodies to type II
collagen are not observed in some RMIA, such as bacterial
cell wall-induced arthritis [44], and the presence of such
antibodies in RMIA does not automatically mean that they
contribute signiﬁcantly to joint destruction [27].
4.2.2. Cytokine Production in Rodent Models of Immune-
Mediated Arthritis. The balance between cellular and
humoral immunity in RMIA, as in RA, is attributed to
variations in cytokine expression patterns in immunoregu-
latory cells, particularly T-helper (Th) lymphocytes. Auto-
immune diseases have been postulated to be dependent on
Th1 cells (which regulate cell-mediated processes marshaled
to counter tumor cells and intracellular pathogens) more so
than on Th2 cells (which generally drive humoral immune
responses to vanquish extracellular organisms). Expression
of Th1 versus Th2 cytokines in AIA changes over time
and is subject to control by sensory innervation [124].
Overactivation of either Th pathway can cause disease, and
either pathway can downregulate the other. Furthermore,
other classes of Th cells have been described, some of which
play a role in autoimmune arthritis (e.g., Th17 cells [125]).
While the original Th1/Th2 hypothesis of immune control
was developed in mice [126], the recent literature reveals
that cytokine patterns in rodent and human diseases seldom
follow an exclusive Th1-inducing or Th2-inducing pattern.
A complex web of chemokines and cytokines controls
the immune response in joint tissue under normal cir-
cumstances. The balance between the functions of these
molecules determines whether or not intra-articular inﬂam-
matory responses are transient and reparative or persistent
and destructive. In general, immune-mediated joint disease
results from overproduction of proinﬂammatory (e.g., IL-
1, IL-6, IL-17, and TNF-α) and proerosive (e.g., receptor
activator of NFκB ligand (RANKL)) factors, hyperactivity
of proinﬂammatory and proerosive signaling pathways, or a
reduction in cytokines (e.g., IL-4, IL-10, and transforming
growth factor-β (TGF-β)) and soluble receptors (e.g., IL-
1ra, soluble TNF receptor (sTNFR)) that antagonize the
proinﬂammatory response [127–129]. Abnormalities in the
local (intra-articular and/or periarticular) or systemic (cir-
culating) levels of such mediators have been reported in RA
[130] and many RMIA, including AIA [94], CIA [93], and
SCW [131].
The large number of mediators involved in regulat-
ing immune-mediated arthritis implies that one or a few
molecules may serve as “master cytokines” [127], early
expression of which is the main upstream incident that
induces all other events needed to launch and sustain arthri-
tis. The master proinﬂammatory cytokines which appear to
drive immune-mediated joint disease in RA and RMIA are
IL-1 (especially the inducible β form) and TNF-α [132–
135], possibly IL-6 [7], and perhaps others. A good indicator
of a master cytokine in a distinct RMIA or human disease
is superior antiarthritic eﬃcacy by a cytokine inhibitor as
exempliﬁed for CIA (more IL-1 dependent) and AIA (more
TNF dependent) [136]. However, although these master
cytokines can act individually as arthritogens, they can
also act together in synergistic fashion to potentiate joint
inﬂammation; for example, IL-1 [4, 137]a n dI L - 1 7[ 138]
exhibit synergistic activity with TNF-α. Other cytokines—
such as IL-12, IL-15, IL-17, and IL-18 [139–141]—as well as
chemokines, such as chemokine (C-C motif) ligand 2 (CCL2
[142]) and chemokine (C-X-C motif) ligand 8 (CXCL8
[143]), have also been implicated as additional participants
in immune-mediated arthritis but are not thought to
function as master cytokines, at least not in the immune-
mediated joint diseases studied thus far.
Alterations in the balance between pro- and anti-
inﬂammatory molecules occur locally and systemically in
advance of the clinical onset of immune-mediated joint
disease. In induced RMIA, such changes can be demon-
strated by four days after inoculation of the arthritogen,
which is between ﬁve to ten days prior to initial joint
swelling [27, 93, 94]. Proinﬂammatory molecules required
to initiate synovitis are upregulated earlier than proerosive
mediators [93, 94]; this temporal sequence matches the
evolution of structural changes within arthritic joints, where
evidence of acute inﬂammation (edema, leukocyte inﬁltra-
tion, and ﬁbrin extravasation) precedes visible damage to
skeletal structures (osteoclast proliferation, cartilage matrix
degeneration, and skeletal erosion). The increase in local
and systemic chemokine and cytokine levels is accompanied
by enhanced production of other molecules that enhance
inﬂammation (e.g., cyclooxygenase-2 and prostaglandin E2
(PGE2)), skeletal destruction (e.g., MMPs), and vascular
expansion (e.g., platelet-derived growth factor and vascular
endothelial growth factor) [27, 144].8 Journal of Biomedicine and Biotechnology
Despite some overlap in their cytokine signatures, dif-
ferent RMIA have divergent local and systemic proinﬂam-
matory proﬁles. For example, rats with AIA or CIA both
produce enhanced levels of IL-1α,I L - 1 β,a n dT G F - β locally
(inside inﬂamed joints) in conjunction with higher systemic
levels of α1 acid glycoprotein, CCL2, and TGF-β prior to
arthritis onset, and both models also exhibit higher intra-
articular amounts of CCL2, IL-6, PGE2, RANKL, and TGF-
β with more circulating CCL2, IL-1α,I L - 1 β,I L - 6 ,a n d
RANKL [93, 94]. In contrast, prior to arthritis onset, the
pro-arthritic signature of male Lewis rats with AIA includes
no mediator enhancement that was unique to joints but
did have systemic increases in CCL2, IL-17, TGF-β,a n d
TNF-α [94], while female Lewis rats with CIA have locally
higher levels of CCL2 and IL-18 with systemic elevation of
CXCL1 (former designation: KC/GRO) [93]. After clinical
arthritis becomes evident, male rats with AIA uniquely
exhibit local enrichment for IL-17 and TGF-β in conjunction
with systemic increases in IL-17, IL-18, and TNF-α [94],
whereas the distinctive proﬁle in female rats with CIA
includes local augmentation of IL-18 and CXCL1 with
systemic ampliﬁcation of IL-1β [93]. Thus, systemic and
local processes in immune-mediated arthritis are discrete
processes in Lewis rats, driven by multiple mediators with
distinct spatiotemporal patterns of expression. Furthermore,
the “master cytokine” hypothesis applies not only to events
in the joint but also to immunological functions triggered
throughout the individual. This latter premise is supported
by the fact that the two major proinﬂammatory cytokines
were conﬁned to separate compartments in RMIA; IL-1 is
restricted chieﬂy to arthritic joints, while TNF-α is limited
mainly to the circulation [93, 94, 128].
4.2.3. Hormonal Eﬀects on Rodent Models of Immune-
Mediated Arthritis. Both the hypothalamic-pituitary-
gonadal (HPG) axis and the hypothalamic-pituitary-
adrenal (HPA) axis are instrumental in regulating immune
responsiveness, and thus the susceptibility to immune-
mediated arthritis. Adrenal (glucocorticoids) and gonadal
(androgens and estrogens) hormones act as natural immune
suppressors, so a deﬁciency of one or more of these
molecules permits enhanced immune reactivity. Females
appear to rely more on the HPA axis while males seem to
depend more on the HPG axis [145]. The lapse in immune
control by deﬁciencies in certain hormonal axes particularly
enhances cell-mediated (Th1-type) events [145].
The impact of gender on the sensitivity to immune-
mediated arthritis is readily apparent in the clinical setting.
The incidence and severity of joint disease is higher in
females for RA and most RMIA [27, 28]. Exceptions to this
female bias are AbIA [59] and CIA [28] in mice and CIA in
rats [146], where males may exhibit a higher incidence and
develop more severe disease than do females. Administration
of estradiol or castration of male rats results in a higher
susceptibility to SCW [147].
Stress is a major factor in susceptibility to immune-
mediated joint disease. For example, SCW-susceptible Lewis
rats have small adrenal glands and a markedly impaired
ability to release corticotropin and corticosterone (products
of the HPA axis) relative to SCW-resistant F344 animals
[148]. The HPA axis is also a player in AIA in rats as
well as CIA in rats and mice [146]. Persistent production
of stress hormones (e.g., cortisol) and sympathetic system
(emergency (ﬁght or ﬂight)) neurotransmitters, such as
norepinephrine, boosts the baseline homeostatic state into
a constant condition of relative proinﬂammatory readiness
[149]. Despite this trend, the stress of handling has also
been shown to reduce the sensitivity to CIA induction [150],
indicating that due care must be exercised to maintain iden-
tical husbandry practices to avoid confounding hormonal
ﬂuctuations among treatment groups. A reasonable practice
in some settings will be to include untreated controls as
well to ensure that a profound stress-induced deviation in
the vehicle-treated cohort does not impede the ability to
diﬀerentiate antiarthritic eﬃcacy from handling stress.
5.Objective3:Recommended RodentModels
of Immune-MediatedArthritis for Use as
RheumatoidArthritisSurrogatesin
PreclinicalDrug Development
The choice of RMIA depends on several factors. The ﬁrst is
the nature of the question being investigated. Basic research
may be pursued using any RMIA, but where available
a mouse model that has been genetically engineered to
overexpress or lack a particular gene often provides the
most straightforward means of testing a molecule-speciﬁc
hypothesis. Examples include the use of IL-1ra knockout
mice [33, 80] or TNF-transgenic mice [34, 77, 151, 152]
to assess the impact of IL-1 (without interference by its
endogenous soluble receptor, IL-1ra) or excessive TNF-α on
arthritis progression, respectively. The second factor will be
the reproducibility of the model. For example, essentially
100% of animals induced to develop AIA will actually
present with acute disease by 9 days after initial inoculation
with the arthritogen, and 100% of rats treated to produced
chronic SCW will undergo reactivation of residual disease
within 1 to 2 days of reinjecting the arthritogen. Such
reliableinductionpermitstreatmentgroupstobecompletely
ﬁlled at one time. In contrast, the incidence of CIA in
Lewis rats varies from 60% to 90% across laboratories,
and arthritis develops over approximately a 5-day period
usually starting 11 days after immunization. Accordingly,
treatment groups in CIA studies must be enrolled over time,
which complicates the treatment matrix of the study. Both
genetically engineered and spontaneous RMIA also tend to
require sporadic enrollment as the onset of disease may be
spread over days to weeks. The third factor will be cost.
Genetically engineered and spontaneous disease models may
be quite expensive. Spontaneous arthritis in MRL/lpr mice
typically does not strike until ﬁve or more months of age
[87], which will increase the husbandry cost relative to
shorter models.
The most suitable RMIA for preclinical development
are the induced diseases that have been proven to predict
the responsiveness of human RA patients: AIA, CIA, and
SCW [37, 153]( T a b l e2). The structural lesions in CIA areJournal of Biomedicine and Biotechnology 9
more analogous to human RA [38, 39]. However, AIA has
been used more extensively for pharmaceutical testing, so
more data exist for cross-species comparison of antiarthritic
eﬃcacy. In our experience, all three of these models may be
reliably elicited in rats, while mice develop CIA but are rela-
tivelyresistanttoclassicAIA[48]andSCW[28,44].Asnoted
above, mouse CIA exhibits a more variable disease pattern
relative to the rat counterpart, and murine joints are very
small. Accordingly, we recommend that preclinical eﬃcacy
studiesofantiarthritic agentsinRMIAbeundertakeninrats.
Several other practical reasons recommend rat models
of arthritis over mouse models if equivalent systems are
available in both species (e.g., CIA). One reason for this
position is that rats are larger, so certain procedures are more
readily accomplished in this species. Ante mortem examples
include intra-articular injections and blood sampling (for
biomarker analysis), while the most critical postmortem
instance is tissue trimming (to consistently orient joints for
histologic sectioning). A second reason for preferring rats
is that the distribution and extent of inﬂammatory changes
in arthritic joints is more reproducible, typically developing
ﬁrst as a symmetric swelling of both hind paws before
progressing to both fore paws [93, 94]. In contrast, mice
inoculated with an arthritogenic agent typically present ﬁrst
withmodestswellingofonlyoneforepaworonehindpaw—
and often only of a single interphalangeal (toe) joint. A third
reasonforfavoringratsisthatknowledgeregardingthemany
genes that control induction of immune-mediated arthritis
is better understood in this species [27, 28]. Potential
disadvantages of using rat arthritis models include the larger
specimen size, thereby requiring removal of the phalanges
(with loss of their joints to analysis) and more cassettes for
histologic processing and the more limited ability for genetic
engineering (especially gene targeting (knockout)) in rats
versus mice. These drawbacks are minor when compared
to the beneﬁts oﬀered by the more reproducible and easily
manipulated rat-based RMIAs.
6.Objective4:SuitableProceduresfor
Reproducible Productionand Appropriate
Assessment of Rat Models of
Immune-MediatedArthritis
Thissectionbrieﬂysummarizestheexperimentalprocedures
employed by our laboratory to reproducibly generate and
analyzeRMIAforan industrial preclinical drugdevelopment
program. The workhorse models are rat AIA-Myc, rat CIA,
and to a much lesser degree rat SCW (Table 2). These RMIA
were selected because of their widespread acceptance, and
especially because of their utility as surrogates for predicting
the response of RA patients to antiarthritic treatments [37,
153]. Novel molecules are tested ﬁrst in AIA-Myc (as rats
develop arthritis in a highly predictable time frame and
with a very uniform morphologic pattern) and then in rat
CIA (due to its greater degree of similarity to RA). Drug
candidatesaretestedinSCW,andoccasionallyinmouseCIA,
only to provide more data for comparing the relative eﬃcacy
of lead candidates slated for human clinical trials (Table 3).
6.1. Induction of Rodent Models of Immune-Mediated
Arthritis. All in vivo RMIA should be undertaken in
accredited facilities (e.g., by the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC)) in accordance with appropriate regulatory
guidelines (e.g., “Guide for the Care and Use of Labora-
tory Animals” (The National Academies Press, Washington,
D.C.)). Humane endpoints and veterinary care needs should
be clearly outlined in animal care and use protocols and
approved by the Institutional Animal Care and Use Commit-
tee in advance. In general,analgesics cannot be given because
their anti-inﬂammatory activities tend to inhibit arthritis
induction and progression. Instead, additional veterinary
support such as ﬂuid therapy, easier access to nutritional
sources (e.g., food pellets placed at ﬂoor level), and/or
supplemental cushioning may be provided during advanced
stages of disease. The most humane practice, which is always
followed in our laboratory, is to limit the length of RMIA to
the shortest possible time required to answer a given exper-
imental question. This period is usually one week after the
onset of clinical disease in our AIA, CIA, and SCW models.
Adjuvant-Induced Arthritis. T h i sm o d e li sp r o d u c e di n
young adult (7- to 8-week-old), male Lewis rats. Animals are
inoculated with a single intradermal injection at the tail base
of heat-killed Mycobacterium tuberculosis H37Ra (0.5mg;
Difco Laboratories, Detroit, MI) suspended in 0.05mL
paraﬃn oil (Crescent Chemical Co., Hauppauge, NY).
Animals are acclimated for one week and then randomly
assigned to treatment groups (n = 6 to 8). This group size is
used because interindividual variability in the initial disease
severity and the day of onset is minimal [4]. Arthritis reliably
develops in both hind paws of 100% of the animals on the
9th day after arthritogen inoculation [4].
The course of rat AIA-Myc can be separated into three
stages using a combination of macroscopic and microscopic
ﬁndings [94]. The “preclinical” phase extends from the day
of arthritogen administration until the day of disease onset
(which is designated Study Day 0). The “acute clinical”
phase, encompassing the peak of active disease, extends from
S t u d yD a y0t oS t u d yD a y1 0a n di sc h a r a c t e r i z e db yb o d y
weight loss, progressive inﬂammation and skeletal erosion
in the hind paws and knees (Figure 2(c)), and the onset
of disease in the forepaws (typically at Study Day 7). The
“chronic clinical” phase represents all times beyond Study
Day 11, at which time lesions have stabilized. Leukocyte
and osteoclast numbers begin to regress by approximately
four weeks after disease onset [8], presumably because the
total loss of articular cartilage and extensive destruction of
adjacent bone has removed the inciting antigen.
Collagen-Induced Arthritis. This model is performed in
young adult (7- to 8-week-old), female Lewis rats. Ani-
mals are immunized by intradermal injection of emulsiﬁed
porcine type II collagen (Chondrex, Redmond, WA) in IFA
at ten diﬀerent sites (100μL per site) over the back; other
researchers use a lesser number of inoculations (e.g., four
[37]), which result in less aggressive joint involvement. The
arthritogen is prepared by dissolving collagen (10mg) in10 Journal of Biomedicine and Biotechnology
Table 2: Initiation of major induced rat models of immune-mediated arthritis commonly used in preclinical development.
Model Inciting agents Adjuvant Strain Gender Inoculation route Day of disease
onset Incidence Group
size
Adjuvant-
induced
arthritis
(AIA-Myc)
Mycobacterium
tuberculosis H37Ra
(heat-killed)
Paraﬃn oil Lewis Male Intradermal (once
at the tail base) 9 100% 6o r
more
Collagen-
induced
arthritis (CIA)
Type II collagen
(porcine)
Incomplete
Freund’s
adjuvant
Lewis Female Intradermal (10
sites over the back) 9t o1 1 80% up
to 100%
8o r
more
Streptococcal
cell
wall-induced
arthritis
(SCW)
Cell wall
peptidoglycan-
polysaccharide
(PG-PS 100P)
from Streptococcus
pyogenes,G r o u pA ,
strain D58
Phosphate-
buﬀered
saline
Lewis Female
Intra-articular
(induction);
intravenous
(reactivation)
29 or 30
(reactivated)
90% up
to 100%
8o r
more
Table 3:Antiarthriticeﬃcacyvariesamongdiﬀerentrodentmodels
of immune-mediated arthritis.
Arthritis model Species
(strain)
Maximum
inhibition
Adjuvant arthritis, lipoidal
amine (AIA-LA) Rat (Lewis) 20–30%
Adjuvant arthritis,
Mycobacterium (AIA-Myc) Rat (Lewis) 30–60%
Collagen-induced arthritis
(CIA) Rat (DA) ∼25%
Collagen-induced arthritis
(CIA) Rat (Lewis) 90–100%
Streptococcal cell wall arthritis
(SCW) Rat (Lewis) 90–100%
Collagen-induced arthritis
(CIA)
Mouse
(DBA/1) 90–100%
Treatment regimen: recombinant human interleukin-1 receptor antagonist
(IL-1ra), infused at 5mg/kg/hr for 7 days beginning at disease onset by
subcutaneous osmotic minipump.
0.1N acetic acid (5mL) two days prior to use while stirring
on a rotating plate in the refrigerator. The collagen is then
emulsiﬁed1:1withIFA(DifcoLaboratories),yieldingaﬁnal
concentration of 1mg/mL, using an emulsiﬁcation needle
and glass syringes (Popper and Sons, New Hyde Park, NY).
Animals are acclimated for one week and then randomly
assigned to treatment groups (n = 8). This group size
is used because interindividual variability in initial disease
severity is minimal [93]. Arthritis develops in at least one
hind paw, and usually both, in 80% to 100% of the animals
between the 9th and the 11th day after injection of the
arthritogen.
T h ec o u r s eo fr a tC I Aa l s oc a nb es e p a r a t e di n t ot h r e e
stages using a combination of macroscopic and microscopic
ﬁndings [93]. The “preclinical” phase extends from the day
of collagen immunization until the day of disease onset in
the hind paws (designated Study Day 0). The “acute clinical”
phase, which encompasses the peak of active disease, extends
from Study Day 0 to Study Day 14 and is characterized
by body weight loss, progressive inﬂammation and skeletal
erosion in the hind paws, and the onset of disease in the
forepaws (typically at Study Day 7). The “chronic clinical”
phase represents all times beyond Study Day 14, at which
time lesions have plateaued in both forepaws and hind
paws.
Streptococcal Cell Wall-Induced Arthritis. This model is
undertaken in young adult (7- to 8-week-old), female Lewis
rats using puriﬁed peptidoglycan-polysaccharide (PG-PS)
cell wall polymers isolated from Streptococcus pyogenes,
Group A, D58 strain (PG-PS 100P; Lee Laboratories,
Grayson, GA). The arthritogen is prepared by suspend-
ing PG-PS (0.09mL, containing 600μg of rhamnose) and
phosphate-buﬀered saline (PBS, 0.91mL) by sonication for
10 minutes, after which it is used immediately. Rats are anes-
thetized deeply to permit direct intra-articular injection of
the PG-PS suspension (10μL, containing 6μgo fr h a m n o s e )
into one tibiotarsal (ankle) joint per animal using a 30-gauge
needle; the intra-articular injection is repeated if the diame-
ter of the induced hind paw does not equal or exceed 7.0mm
after 24 hours. Animals are maintained for 4 weeks (to allow
acute inﬂammation to subside into chronic disease), after
which they are randomized by ankle diameter into treatment
groups (n = 8). Arthritis is reactivated on day 29 or 30 after
the initial intra-articular induction by intravenous injection
of PG-PS/PBS suspension (35μL, containing about 200μgo f
rhamnose). Arthritis develops in the injected hind paw in
90% to 100% of the animals between the 1st and the 2nd
daysafterdiseasereactivation.Pawswellingpeaksat72hours
after reactivation and then regresses rapidly over the next
severaldays.Alternatively,SCWpolyarthritismaybeinduced
by parenteral administration (e.g., intraperitoneal) of PG-
PS, with the nature of the lesions depending on how long
clinical and histopathologic analyses are delayed after PG-PS
administration [154]. To our knowledge, no detailed study
has been published deﬁning the progression of either acute
or chronic SCW in rats.Journal of Biomedicine and Biotechnology 11
6.2. Assessment of Arthritis. Analytical tests applied to RMIA
can be separated in three fashions. The ﬁrst is by tiers,
where Tier 1 includes routine screening procedures while
Tier 2 represents specialized methods that are undertaken
only as needed to answer distinct questions. The second
classiﬁcation scheme is to divide the tests by the time frame
during which they are performed (i.e., antemortem versus
postmortem). The ﬁnal categorization is by invasiveness of
thetest.Measurementsoftotalbodyweightandpawswelling
may be taken repeatedly over time without inﬂicting any
wound, and blood sampling to measure serum biomarkers is
minimallyinvasiveaslongasbloodcollectionisnotexcessive
(no more than 0.5% of body weight, or about 1mL of
blood from a 250g rat). In contrast, histopathologic analysis
requires that aﬀected joints be removed and processed prior
to evaluation.
Routine Screening Tests (Tier 1). These methods are used
on all RMIA in our laboratory and include total body
weights, measurement of hind paw swelling, calculation of
bone mineral density (BMD) loss, and histopathology. Total
body weight and paw swelling are evaluated daily from the
day of disease onset throughout the treatment period (and
any recovery period) to provide a graphic representation
of disease progression. Paw swelling is assessed by one of
two techniques: plethysmography [4], which calculates the
degree of paw volume expansion by computing the weight
of ﬂuid displaced by the swollen limb upon immersion in
a water-ﬁlled beaker balanced on a commercial scale, or
caliper measurements to deﬁne the diameter of the aﬀected
joint(s).Plethysmographyisbestsuitedformassivelyswollen
AIA hind paws and calipers for more modestly swollen hind
paws in CIA and SCW, but either technique may be applied
successfully to any of these rat models.
After necropsy, the hind paws are removed at the fur
line (just proximal to the hock (ankle)). One paw is stored
in 70% ethanol at room temperature until dual X-ray
absorptiometry (DXA) can be used to assess BMD loss [4].
The degree of BMD reduction is dictated by the extent of
leukocyte inﬁltration as osteoclast recruitment along bony
surfaces is induced by numerous proinﬂammatory cytokines
[155]; accordingly, bone dissolution is more severe in AIA
(Figure 4), where leukocyte inﬂux is more severe than in
CIA or SCW. The other paw is ﬁxed by immersion in either
70% ethanol (to serve as a potential backup sample for DXA
or a substrate for molecular pathology studies) or either
neutral buﬀered 10% formalin or zinc formalin (to provide
the best morphologic preservation of inﬁltrating leukocytes)
at room temperature for 72 to 96 hours. Fixed specimens
are decalciﬁed in eight serial changes of a 1:4 mixture of
8N formic acid and 1N sodium formate for approximately a
week; more rapid decalciﬁcation may be achieved by using
a 1:1 mixture, but delicate tissue antigens may be too
degraded for subsequent molecular pathology analysis. The
digits (toes) are then removed from the demineralized hind
paws by cutting across the metatarsals (the “arch” of the
“foot”)midwaybetweenthetipofthetoesandthehock,after
which the paw is divided longitudinally into approximately
equal halves by cutting just lateral to the tibia and between
the 2nd and the 3rd digits (Figure 5). The two halves are
placed into a single cassette and processed into paraﬃn
using routine procedures. Embedded specimens are faced to
expose the distal tibia and entire talus, after which several
serial 4- to 8-μm-thick sections are cut.
Routine histopathologic analysis for Tier 1 is performed
using one to three slides. The ﬁrst slide is stained with
hematoxylin and eosin (H&E) for evaluation of general
structuralcharacteristicssuchasleukocyteinﬁltration,skele-
tal erosion, periosteal proliferation, and (in CIA only)
pannus production (Figure 6). The second slide may be
processed by indirect immunohistochemistry or in situ
hybridization to detect the osteoclast marker cathepsin K
[102]. If desired, cathepsin K immunohistochemistry may
be followed by an H&E counterstain to avoid the need for
the H&E-stained slide; this procedure may be automated
for higher throughput. The third slide is stained with either
safranin O or toluidine blue (Figure 6) to evaluate the degree
of matrix integrity in articular cartilage. As the extent of
inﬂammation increases, the articular cartilage loses matrix
proteins and can no longer bind dye [8, 156]. In practice,
the loss of cartilage matrix is so advanced in chronic arthritis
that this latter stain may be omitted if the disease has been
present for more than ﬁve (for AIA) to ten (for CIA) days.
Histopathologic data for Tier 1 screening is performed using
semiquantitative grading scales (normal joint, or minimal,
mild, moderate, or marked disease), which can be rapidly
gathered by an experienced pathologist (10 to 60 seconds
per section for all stains, depending on the complexity of the
lesion).
Specialized Tests (Tier 2). The procedures used in our
laboratory are applied in addition to, not instead of, the
Tier 1 methods. For example, a detailed examination of
local and systemic events in RMIA requires evaluation of
numerousparametersotherthaninvolvementofjointsinthe
distal limbs. Whole blood may be collected for hematologic
counts, or to harvest serum to measure circulating levels of
biomarkers and immune proteins [93, 94]. For comparison,
unﬁxed joints may be homogenized to extract and quantify
local biomarkers [93, 94]. Extra-articular tissues (especially
hematopoietic organs like bone marrow, lymph nodes, or
spleen) may be isolated to correlate tissue leukocyte numbers
to circulating cell counts by ﬂow cytometry or histopathol-
ogy [93, 94]o rt op e r m i te v a l u a t i o no fs y s t e m i cb o n el o s s
at sites distant from aﬀected joints (e.g., lumbar vertebrae
[10]). Diseased joints may be imaged using conventional
radiography [105], computed tomography [26, 157, 158], or
magnetic resonance imaging [157]. Paws may be harvested
and split longitudinally while fresh using a circular, water-
cooleddiamondsaw(e.g.,IsometLowSpeedmodel;Buehler,
Lake Bluﬀ, IL) to provide for more rapid penetration of ﬁxa-
tive; subsequent ﬁxation time can be reduced substantially,
thereby reducing the degradation of delicate antigens and
nucleic acids while retaining good tissue morphology.
The routine Tier 1 semiquantitative histopathologic
analysis may be augmented in Tier 2 by supplementary
endpoints. One common approach is to include additional
special stains to demonstrate other constituents in the12 Journal of Biomedicine and Biotechnology
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Figure 4: Bone mineral density (BMD) of the tibiotarsal region (hock (or “ankle”)) by dual X-ray absorptiometry (DXA) is a rapid means
of evaluating bone integrity in arthritic rodent hind paws. Relative to a nonarthritic control (a), BMD is greatly reduced in multiple bones
(bordered by the yellow rectangle) of a young adult, male Lewis rat with the mycobacterial variant of adjuvant-induced arthritis (AIA-Myc).
These panels are reproduced from [155] with the permission of the American College of Rheumatology.
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Figure 5: Tissue trimming procedure for reliable and reproducible production of high-quality hind paw sections for histopathological
analysis of immune-mediated arthritis in rodents. A skeletal schematic diagram (a) shows the location of the cuts required to isolate the
tibiotarsalregion.Asviewedfromthelateralside(a(leftpanel)),thehindpawisseparatedfromthedistallimbjustabovethetibiotarsal(hock
(or “ankle”)) region at the fur line, and the digits (toes) are removed. From the top (a (right panel)), the hind paw is divided longitudinally
using a cut placed between metatarsals II and III, which will fall just to the outside of the talus (the uppermost bone to the left of the orange
line) and tibia (the distal leg bone (not shown)) that articulates with the talus. The distal tibia ((b), bracketed by forceps) is identiﬁed at the
proximal cut margin of isolated hind paws as an oval white bone with a yellow/brown core of bone marrow. The longitudinal dividing cut
(d) is made from the dorsal side by engaging the blade at the proximal and distal margins of the sample and then cutting straight down;
the dashed black oval indicates the position of the tibia behind the razor blade, indicating that the blade is located just to the side of this
bone. The microscopic structure of hind paw sections taken through this region from a nonarthritic rat (c) will include the joint spaces most
susceptible to induced models of immune-mediated arthritis (asterisks (∗)) as well as the most aﬀected tarsal bones (navicular (N) and talus
(Ta)), the distal tibia (Ti), and sometimes the calcaneus (C (or “heel”)). Histologic stain: hematoxylin and eosin (H&E).Journal of Biomedicine and Biotechnology 13
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Figure 6: Structural lesions of immune-mediated joint disease in arthritic rodents include both skeletal and soft tissue changes. Relative
to nonarthritic control animals ((a) and (c)), young adult, male Lewis rats with the aggressive mycobacterial variant of adjuvant-induced
arthritis (AIA-Myc) ((b) and (c)) develop extensive inﬂammation of the fatty periarticular soft tissues (F) and bone marrow, erosion of
cortical and trabecular bone, loss of physeal (growth plate) cartilage (asterisks (∗)), and exuberant production of periosteal bone (P). Fibrin,
inﬂammatory cells, and (for CIA) pannus are additional features that may be evident on hematoxylin and eosin (H&E)-stained sections ((a)
and (b)). Cartilage degeneration is demonstrated by toluidine blue staining ((c) and (d)), with the normal uniform dark purple labeling
of surface and deep articular cartilage in nonarthritic controls (c) being replaced in inﬂamed joints by loss of staining in the superﬁcial
matrix of arthritic rats (d). Extensive loss of subchondral and trabecular bone (pale white plates and columns adjacent to cartilage) results
from extensive inﬁltration of the bone marrow by inﬂammatory cells (punctate gray/green ﬁelds between bones in (d)). Abbreviations: N =
navicular tarsal bone, Ta = talus, Ti = tibia.
arthritic process, such as markers for blood vessels [101],
diﬀerent populations of leukocytes, or expression of various
proinﬂammatory and proerosive mediators [10]. Another
option is to examine lesions in other joints besides those
of the aﬀected paws. In this regard, preferred choices are
the knee (Figure 7) and the interphalangeal (toe) joints.
Considerable care must be taken to ensure that the specimen
is positioned correctly during trimming so that sections
are oriented in the optimal plane; for example, a frontal
view is preferred for the knee to allow maximal scrutiny
of the articular surface [62]. A ﬁnal variant is to procure
quantitative data from histopathologic sections [101, 102].
Such special analyses require at least some extra time, and
often a great deal of it, so should not be undertaken lightly in
the course of preclinical development programs.
7. Objective 5: Considerations in Model
Selection andExperimentalDesign
The current section will brieﬂy examine several practical
principles that must be contemplated when using the
induced RMIA that we recommend above. Failure to con-
sider such points may delay the launch of studies, result
in their premature termination, or require their repetition.14 Journal of Biomedicine and Biotechnology
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Figure 7: Tissue trimming procedure for reliable and reproducible production of high-quality sections through the rodent femorotibial
(knee) joint. A skeletal schematic diagram (a) shows the location of the cut required to isolate the knee region at the appropriate plane, as
viewed from the lateral side. The tissuealong the cranial (front)surface of the knee is removed ((b),oriented with the distal tibia to the left) a
few millimeters at a time while holding the razor blade parallel with the cranial surface of the tibia. The appearance of the properly trimmed
joint (d) will show the distal femur (F) and proximal tibia (T) separated by the joint space (asterisk (∗)), as well as the physis (growth plate)
forbothbones(arrows).Theappearanceofthecorrespondinghistologicsectionfromanonarthriticrat(c)revealsadditionalfeatureswithin
the joint space including the menisci (M) associated with the femoral condyles and the cruciate ligaments (X). Histologic stain: hematoxylin
and eosin (H&E).
Time spent in optimizing RMIA up front will save signiﬁcant
eﬀort, money, and time when building a research program
and generating the preclinical portion of a product registra-
tion package.
7.1. Genetic Background. In general, routine rodent arthritis
studies should be performed in strains that are inherently
sensitive to induction of immune-mediated joint disease.
In our experience, the preferred wild-type strains are Lewis
rats, which exhibit an intermediate susceptibility to disease
(Figure 1), and DBA/1 mice. Each laboratory will have to
validate that the animals from their supplier are suﬃciently
vulnerable to arthritis induction and will have to ensure that
genetic drift does not alter the substrain’s sensitivity over
time [29].
7.2. Choice of Inducing Agent. The type of adjuvant inﬂu-
ences the course of RMIA. As shown in Figure 2,r a t s
with AIA-LA and AIA-Myc have diﬀerent patterns of lesions
and divergent dose responses to antiarthritic molecules.
Similarly, induction of CIA in mice using the weak adjuvant
IFA results in reduced susceptibility to arthritis relative to
animals in which the carrier was complete Freund’s adjuvant
(CFA) [159]. The source of adjuvant may impact the extent
of disease as well (Figures 1 and 3).
7.3. Microbial Flora. The bacterial composition may play a
large role in deﬁning the sensitivity of various rodent strains
toarthritogenicstimuli.Forexample,arthritis-resistantF344
rats become vulnerable to AIA when housed under germfree
conditions [160]. In contrast, the germfree state preventsJournal of Biomedicine and Biotechnology 15
development of inﬂammatory diseases in joints (and the
intestinal tract) of HLA-B27-transgenic rats [81, 82]. In
our experience, preclinical development programs are best
performed in rodent strains (such as Lewis rats), where
an intermediate susceptibility to arthritis is compatible
with the presence of a normal microbial complement,
thereby avoiding the need for expensive germfree husbandry
practices.
7.4. Treatment Regimen. The responsiveness of RMIA to
antiarthritic agents is variable. Importantly, the pharmaco-
logical target must be a major player in the RMIA selected.
In general, aggressive RMIA are unresponsive to weak anti-
inﬂammatory agents like nonsteroidal anti-inﬂammatory
agents (NSAIDs)—although AIA is easily inhibited with
cyclooxygenase inhibitors—but are sensitive to more potent
molecules (e.g., anticytokine biologics, corticosteroids, and
disease-modifying antirheumatic drugs (DMARDS)). Less
destructive RMIA like CIA and SCW are more responsive
to all classes of agents. In fact, each RMIA embodies
one distinct disease in one individual (inbred strain) as
contrasted to human RA, which represents a continuum
of disease expressions in an outbred population. Thus, the
heterogeneity of pharmacological responses in RMIA reﬂects
the heterogeneity of therapeutic success in RA.
The impact of antiarthritic agents on immune-mediated
arthritis is dependent on several factors. The most obvious is
dose.Higherdosesofantiarthriticmoleculesusuallyproduce
greater reductions in arthritis parameters than do lower
doses [4]. That said, the shape of the dose-response curve
will not always be linear (Figure 2)[ 8]. A second factor is
the time at which an antiarthritic agent is administered. The
production of proinﬂammatory mediators waxes and wanes
[93, 94, 161], so achieving a therapeutic eﬀect is depen-
dent on when therapeutic molecules are administered—
particularly when cytokines and chemokines are targeted
with speciﬁc inhibitors. For example, cyclosporin A is an
eﬀective immunosuppressant that can signiﬁcantly inhibit
hind paw swelling in rat CIA (Figure 8). However, shifting
the time frame over which cyclosporin A is delivered can
even potentiate disease [162], resulting in an earlier onset or
increased severity, or delay disease onset (Figure 8). A ﬁnal
factor is the nature of the target for an antiarthritic agent.
For example, osteoprotegerin (OPG) is a soluble receptor
for the proerosive ligand RANKL. Administration of OPG to
rats with AIA-Myc essentially halts bone erosions even in the
face of severe joint inﬂammation but has very little impact
on the inﬂammatory component of disease [8, 99, 156]. In
contrast,IL-1raandsTNFR-1areinhibitorsofIL-1andTNF-
α, respectively. Administration of these latter two agents
blocks inﬂammation, and as a secondary consequence it
prevents skeletal damage as well [4]. Thus, the nature of
anticipated therapeutic beneﬁt may dictate the design of the
experiment and/or analysis.
8. Summary
Various rodent models of arthritis are the conventional
means of evaluating hypothetical mechanisms of immune-
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Figure 8: The eﬀect of cyclosporin A (CsA), a potent immunosup-
pressant, on the extent of collagen-induced arthritis (CIA) in young
adult, female Lewis rats depends on the treatment schedule. The
course of CIA in untreated animals (arthritiscontrol) is represented
by the solid blue line with triangular data points. Administration
of CsA on the day of arthritis induction (designated as d0) for 7
consecutive days (d0 to d7) substantially inhibits hind paw swelling
(orange-dotted line with inverted triangles). Early but abbreviated
treatment with CsA (d0 to d4) delays disease onset but does not
impact its ultimate severity (solid red line with squares). Delayed
exposure to CsA (d7 to d14) greatly exacerbated the degree of
hind paw swelling (green-dotted line with circles). Bars associated
with data points represent standard error of the mean. Treatment
regimen: CsA was given at 25mg/kg/day by gavage.
mediated joint disease and the comparative eﬃcacy of
novel drug candidates with potential antiarthritic eﬃcacy
during preclinical development. The workhorse models are
polyarthritides in rats and mice induced by injecting either
bacterial (especially mycobacterial (AIA-Myc) or streptococ-
cal (SCW)) fragments or collagen type II (usually from a
nonrodent mammalian source (CIA)) in adjuvant. Eﬃcacy
is typically evaluated by a combination of semiquantitative
and quantitative techniques including clinical measurements
(e.g., paw volume and serum biomarker concentrations),
noninvasive imaging (e.g., bone density analysis and com-
puted tomography), and histopathology scores (e.g., lesion
scores for inﬂammation, joint erosion, osteophyte produc-
tion, and cartilage degradation).
The extent and severity of arthritis depends on both
the experimental methodology (e.g., inciting agent, adju-
vant, number, and placement of sensitizing injections)
and individual physiologic parameters (e.g., age, gender,
and genetics). Similarly, the eﬀectiveness of antiarthritic
molecules varies with the nature of the agent, the therapeutic
regimen (e.g., dose, route, and schedule of treatment),
and the choice of rodent arthritis model. In our expe-
rience, rat models of AIA, CIA, and SCW are preferred
platforms for preclinical drug development because these
rat systems are more reproducible among individuals and
across studies than are corresponding mouse models. Of16 Journal of Biomedicine and Biotechnology
these three rat models, AIA is more severe but exhibits
the most consistent lesions among study mates and across
studies, while CIA delivers joint lesions in rodents with
a histopathologic appearance that better resembles that of
the human rheumatoid arthritis joint. All the rat models
are driven by relative overactivity of proinﬂammatory and
proerosive signaling cascades, but the dominant cytokines
diﬀer among the models. As with human clinical experience,
the eﬃcacy of various antiarthritic molecules diﬀers among
rodentarthritismodels,especiallywhentheagentisaspeciﬁc
cytokine inhibitor.
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